Summary of Significant Accounting Policies and Basis of Presentation - Additional Information (Detail) - USD ($) $ in Thousands |
|
9 Months Ended |
|
Oct. 23, 2013 |
Sep. 30, 2016 |
Dec. 31, 2015 |
| Accounting Policies [Line Items] |
|
|
|
| Deferred revenue on upfront payment |
|
$ 1,500
|
$ 1,500
|
| Ildong [Member] |
|
|
|
| Accounting Policies [Line Items] |
|
|
|
| Upfront payment received |
$ 1,500
|
|
|
| Deferred revenue on upfront payment |
|
$ 1,500
|
$ 1,500
|
| Aggregate potential milestone payments receivable |
$ 3,500
|
|
|
| Percentage of payment received upon manufacturing cost per tablet |
5.00%
|
|
|
| Agreement expiration period |
|
15 years
|
|
| Ildong [Member] | Minimum [Member] |
|
|
|
| Accounting Policies [Line Items] |
|
|
|
| Percentage of purchase price per unit on net sales |
31.50%
|
|
|
| Ildong [Member] | Maximum [Member] |
|
|
|
| Accounting Policies [Line Items] |
|
|
|
| Percentage of purchase price per unit on net sales |
36.50%
|
|
|
| Ildong [Member] | US Food and Drug Administration or European Medicines Agency [Member] |
|
|
|
| Accounting Policies [Line Items] |
|
|
|
| Potential milestone payment receivable upon submission of drug |
$ 1,000
|
|
|
| Potential milestone payment receivable upon approval of drug |
1,500
|
|
|
| Ildong [Member] | Republic of Korea [Member] |
|
|
|
| Accounting Policies [Line Items] |
|
|
|
| Potential milestone payment receivable upon approval of drug |
$ 1,000
|
|
|